10:45 AM EST, 03/03/2025 (MT Newswires) -- Nuvation Bio ( NUVB ) said Monday that it secured up to $250 million in non-dilutive financing deals with Sagard Healthcare Partners.

The biopharmaceutical company said the deals include a royalty interest financing, under which Sagard agreed to provide Nuvation Bio ( NUVB ) with an upfront $150 million cash payment in exchange for tiered royalties on taletrectinib's net sales in the US.

In addition, Sagard also committed to provide Nuvation Bio ( NUVB ) with a five-year, senior secured term loan of up to $100 million, according to the statement.

Shares of Nuvation Bio ( NUVB ) were up over 3% in recent trading.

Price: 2.04, Change: +0.07, Percent Change: +3.40